ONCO Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -2892.23% compared to Onconetix, Inc.'s net margin of --. Onconetix, Inc.'s return on equity of -377.25% beat CEL-SCI Corp.'s return on equity of -230.36%.

Onconetix, Inc. has a consensus price target of --, signalling upside risk potential of 2124901.06%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 718.88%. Given that Onconetix, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Onconetix, Inc. is more attractive than CEL-SCI Corp..

Onconetix, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Onconetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onconetix, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Onconetix, Inc. quarterly revenues are $303.7K, which are larger than CEL-SCI Corp. quarterly revenues of --. Onconetix, Inc.'s net income of -$8.8M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Onconetix, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onconetix, Inc. is 0.68x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -2892.23% compared to Onconetix, Inc.'s net margin of --. Onconetix, Inc.'s return on equity of -377.25% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Onconetix, Inc. has a consensus price target of --, signalling upside risk potential of 2124901.06%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 769.47%. Given that Onconetix, Inc. has higher upside potential than GT Biopharma, Inc., analysts believe Onconetix, Inc. is more attractive than GT Biopharma, Inc..

Onconetix, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Onconetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onconetix, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Onconetix, Inc. quarterly revenues are $303.7K, which are larger than GT Biopharma, Inc. quarterly revenues of --. Onconetix, Inc.'s net income of -$8.8M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Onconetix, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onconetix, Inc. is 0.68x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -2892.23% compared to Onconetix, Inc.'s net margin of -953.4%. Onconetix, Inc.'s return on equity of -377.25% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Onconetix, Inc. has a consensus price target of --, signalling upside risk potential of 2124901.06%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1203.4%. Given that Onconetix, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe Onconetix, Inc. is more attractive than IGC Pharma, Inc..

Onconetix, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Onconetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onconetix, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Onconetix, Inc. quarterly revenues are $303.7K, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Onconetix, Inc.'s net income of -$8.8M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Onconetix, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onconetix, Inc. is 0.68x versus 22.31x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.